Emphasize Adherence to Help Boost Hep C Cure Rates
January 2016
More hepatitis C patients will now be treated...due to updated guidelines and a push for fewer payer restrictions.
Most patients will get one or two of the new oral meds, Daklinza (daclatasvir)...Harvoni (ledipasvir/sofosbuvir)...Olysio (simeprevir)...Sovaldi (sofosbuvir)...Technivie (ombitasvir/paritaprevir/ritonavir)...or Viekira Pak (ombitasvir/paritaprevir/ritonavir and dasabuvir).
Expect most patients to be treated for 12, 16, or 24 weeks...often based on whether they have cirrhosis or have been treated before.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote